OrbiMed Israel BioFund GP Limited Partnership 13D and 13G filings for Chemomab Therapeutics Ltd.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-09-16 4:34 pm Sale |
2024-09-12 | 13D | Chemomab Therapeutics Ltd. CMMB |
OrbiMed Israel BioFund GP Limited Partnership | 1,860,906 9.990% |
-409,185 (-18.03%) |
Filing |
| 2024-03-11 7:19 pm Unchanged |
2024-03-11 | 13D | Chemomab Therapeutics Ltd. CMMB |
OrbiMed Israel BioFund GP Limited Partnership | 2,270,091 16.000% |
0 (Unchanged) |
Filing |
| 2023-11-15 4:35 pm Unchanged |
2023-11-14 | 13D | Chemomab Therapeutics Ltd. CMMB |
OrbiMed Israel BioFund GP Limited Partnership | 2,270,091 18.300% |
0 (Unchanged) |
Filing |
| 2023-01-05 4:31 pm Sale |
2023-01-03 | 13D | Chemomab Therapeutics Ltd. CMMB |
OrbiMed Israel BioFund GP Limited Partnership | 2,270,091 19.700% |
-49,869,729 (-95.65%) |
Filing |
| 2021-03-26 4:06 pm Purchase |
2021-03-16 | 13D | Chemomab Therapeutics Ltd. CMMB |
OrbiMed Israel BioFund GP Limited Partnership | 52,139,820 24.300% |
52,139,820 (New Position) |
Filing |